Microtest has signed an agreement with UK-based biopharmaceutical company Antisoma to begin the aseptic manufacturing of AS1411, a new drug being developed for the treatment of various cancers. Under the terms of the agreement, Microtest will be responsible for the formulation and aseptic fill/finish of AS1411 material for upcoming Phase II trials. Microtest will also be responsible for stability testing of the AS1411 product. “AS1411 is the first aptamer to be tested in cancer clinical t...